KS Evaluation and Clinical Benefit Form: RK1 NCT00310128 Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Source Form: NCI FormBuilder:


Versions (3) ▾
  1. 8/26/12
  2. 1/9/15
  3. 6/21/15
Uploaded on:

June 21, 2015

No DOI assigned. To request one pleaselog in.
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

KS Evaluation and Clinical Benefit Form: RK1 NCT00310128

No Instruction available.

  1. StudyEvent: KS Evaluation and Clinical Benefit Form: RK1
    1. No Instruction available.
Patient demographics
History And Symptoms
Evaluation Of Cutaneous Lesions
Evaluation Of Marker Lesions
Evaluation Of Foot Ks
Evaluation Of Oral Cavity
Lesions Measurements
Edema Evaluation
Evaluation Of Extremity Edema
Evaluation Of Periorbital Edema
Evaluation Of Scrotal/genital Swelling
Evaluation Of Visceral Disease
Interventions (in Addition To Study Drug Therapy)
Overall Assessment